Maria L Jison MD
Critical Care Medicine
Senior Medical Lead/Medical Director, AstraZeneca
Join to View Full Profile
1 MedImmune WayGaithersburg, MD 20878
Dr. Jison is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Physician/Entreprenuer, Board certified in pulmonary-critical care medicine, experienced in global late phase (Ph3) clinical development, global clinical trials, protocol development, regulatory interactions, advisory boards, and FDA pre-market medical device review. Small business owner and President of Maximus Medical Billing LLC, a professional, multi-specialty medical billing company providing electronic claims submission for physician practices. Part time practicing Pulmonologist
Education & Training
Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2002
University of North Carolina HospitalsResidency, Internal Medicine, 1996 - 1999
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1996
Certifications & Licensure
MD State Medical License 1999 - 2026
NC State Medical License 1997 - 2022
VA State Medical License 2005 - 2022
Awards, Honors, & Recognition
- CHEST Foundation Humanitarian Award ACCP, 2006
Publications & Presentations
PubMed
- Correspondence to 'Interleukin-5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils'.Christopher McCrae, Maria L Jison, Andrew Menzies-Gow
Allergy. 2025-04-10 - Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies.Gerard J Criner, Dave Singh, Alberto Papi, Maria Jison, Natalya Makulova
Therapeutic Advances in Respiratory Disease. 2025-03-12 - Effect of benralizumab treatment on the airway microbiome in COPD.Koirobi Haldar, Vijay Mistry, Mathew Richardson, Corinne Hamblet, Maria Jison
ERJ Open Research. 2025-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
